Suppr超能文献

中性粒细胞弹性蛋白酶抑制剂(西维来司他钠)和自由基清除剂(依达拉奉)对脂多糖诱导的大鼠急性肺损伤的联合作用。

Combined effects of a neutrophil elastase inhibitor (sivelestat sodium) and a free radical scavenger (edaravone) on lipopolysaccharide-induced acute lung injury in rats.

机构信息

Department of Anesthesiology, Second Military Medical University, 800 Xiangyin Road, 200433, Shanghai, People's Republic of China.

出版信息

Inflamm Res. 2012 Jun;61(6):563-9. doi: 10.1007/s00011-012-0445-7. Epub 2012 Apr 7.

Abstract

OBJECTIVE AND DESIGN

The present study aimed to investigate the combined effects of a neutrophil elastase inhibitor, sivelestat sodium, with a free radical scavenger, edaravone, on lipolysaccharide (LPS)-induced acute lung injury (ALI).

MATERIALS AND METHODS

Adult male Sprague-Dawley rats were anesthetized and instilled intratracheally with 2 mg/kg LPS. Sivelestat sodium (10 mg/kg, i.p.) and/or edaravone (8 mg/kg, i.p.) were administered 1 h after LPS instillation. The severity of pulmonary injuries was evaluated 12 h after inducing acute lung injury.

RESULTS

In lung tissues, either sivelestat or edaravone treatment alone showed significant protective effects against neutrophil infiltration and tissue injury, as demonstrated by myeloperoxidase activity and histopathological analysis. Sivelestat or edaravone treatment also attenuated the LPS-induced production of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α) in rat lungs. However, the LPS-induced elevation of malondialdehyde levels in rat lungs was reduced only by edaravone, but not by sivelestat. In addition, combined treatment with both sivelestat and edaravone demonstrated additive protective effects on LPS-induced lung injury, compared with single treatments.

CONCLUSIONS

Combination of sivelestat and edaravone shows promise as a new treatment option for ALI/acute respiratory distress syndrome patients.

摘要

目的和设计

本研究旨在探讨中性粒细胞弹性蛋白酶抑制剂西维来司他钠与自由基清除剂依达拉奉联合应用对脂多糖(LPS)诱导的急性肺损伤(ALI)的影响。

材料和方法

成年雄性 Sprague-Dawley 大鼠麻醉后经气管内滴注 2mg/kg LPS。LPS 滴注后 1 小时给予西维来司他钠(10mg/kg,腹腔注射)和/或依达拉奉(8mg/kg,腹腔注射)。诱导急性肺损伤 12 小时后评估肺损伤的严重程度。

结果

在肺组织中,单独使用西维来司他或依达拉奉治疗均可显著减轻中性粒细胞浸润和组织损伤,表现为髓过氧化物酶活性和组织病理学分析。西维来司他或依达拉奉治疗还可减轻 LPS 诱导的大鼠肺内促炎细胞因子白细胞介素(IL)-6 和肿瘤坏死因子-α(TNF-α)的产生。然而,只有依达拉奉可降低 LPS 诱导的大鼠肺内丙二醛水平的升高,而西维来司他则不能。此外,与单一治疗相比,西维来司他和依达拉奉联合治疗对 LPS 诱导的肺损伤具有相加的保护作用。

结论

西维来司他和依达拉奉的联合治疗为 ALI/急性呼吸窘迫综合征患者提供了一种新的治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验